Letter to the EditorCysteamine, a pro-BDNF drug, as an adjunctive treatment for schizophrenia
Section snippets
Role of funding source
None.
Contributors
Dr. Kirkpatrick designed the study. Dr. Miller was the clinical rater. Dr. Pillai performed assays for BDNF. Drs. Buckley and Miller managed the literature searches. Dr. Buckley wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.
Conflict of interest
In the past 12 months, Dr. Buckley has served as a consultant for the NIMH and has received grant/research support from Sunovion and the NIMH.
In the past 12 months, Dr. Miller has received grant/research support from the National Institute of Mental Health (NIMH), the American Psychiatric Association, and Georgia Regents University; and honoraria from Medscape and Insight Consulting Group.
In the past 12 months, Dr. Pillai has received grant/research support from the National Institute of Mental
Acknowledgments
The authors would like to thank Dawn Montoya, Becca Nichols, and Edna Stirewalt for assistance.
References (15)
- et al.
Brain derived neurotropic factor in first-episode psychosis
Schizophr. Res.
(2007) - et al.
The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine
J. Pediatr.
(2003) - et al.
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)
Schizophr. Res.
(2008) - et al.
Cysteamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders
J. Biol. Chem.
(2003) - et al.
Inhibition of “tissue” transglutaminase increases cell survival by preventing apoptosis
J. Biol. Chem.
(1999) - et al.
Therapeutic possibilities of cysteamine in the treatment of schizophrenia
Med. Hypotheses
(2007) Cysteamine-related agents could be potential antidepressants through increasing central BDNF levels
Med. Hypotheses
(2006)
Cited by (3)
Angiogenesis in the pathophysiology of schizophrenia - A comprehensive review and a conceptual hypothesis
2015, Life SciencesCitation Excerpt :BDNF, other neurotrophins, pro-neurotrophic factors and corresponding downstream signaling pathway interveners, have been considered as potential adjunctive treatment options, although they comprise numerous methodological and pharmacokinetic problems [220]. Recent investigation has captured interest in cysteamine (an FDA-approved precursor of cystamine), a pro-BDNF drug with anti-oxidant and anti-apoptotic properties [28,281,282]. Although promising, a recent open-labeled trial testing cysteamine in SZ patients medicated with second-generation antipsychotics, did not find considerable effects on symptoms and cognitive function for the two patients enrolled, but found increased sequential BDNF levels that were, however, only measured in one single patient [28].
Therapeutic Applications of Cysteamine and Cystamine in Neurodegenerative and Neuropsychiatric Diseases
2019, Frontiers in NeurologyCysteamine prevents vascular leakage through inhibiting transglutaminase in diabetic retina
2017, Journal of Endocrinology